Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (Nasdaq: GILD) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Gilead's business and see what CAPS investors are saying about the stock right now.
Gilead facts
Headquarters (Founded)
Foster City, Calif. (1987)
Market Cap
$41.6 billion
Industry
Biotechnology
Trailing-12-Month Revenue
$6.4 billion
Management
Dr. John Martin (since 1996) COO Dr. John Milligan (since 2007)
Return on Capital (Average, Past 3 Years)
30.6%
Cash / Debt
$3.3 billion / $1.3 billion
Competitors
GlaxoSmithKline (NYSE: GSK) Abbott Labs (NYSE: ABT)
CAPS Members Bullish on GILD Also Bullish on Continued...
Brian D. Pacampara is an investment expert and analyst for the Motley Fool.
Be the first to read Brian D. Pacampara's column. Sign up today and receive Townhall.com delivered each morning to your inbox.